Advances in antibiotics.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002509:Cephaloridine / Q000627:therapeutic use; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005672:Fusidic Acid / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007239:Infections / Q000188:drug therapy*; D008034:Lincomycin / Q000627:therapeutic use; D009268:Nalidixic Acid / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012293:Rifampin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D010406:Penicillins; D009268:Nalidixic Acid; D005672:Fusidic Acid; D008034:Lincomycin; D013420:Sulfamethoxazole; D002509:Cephaloridine; D012293:Rifampin